Abstract
Posttransplant anemia (PTA) is a common complication of pediatric kidney transplantation, with a prevalence ranging from 22 to 85%. PTA is categorized as early (within 6 months posttransplant) and late (>6 months posttransplant). Early PTA is typically associated with surgical blood losses and iron deficiency. Late PTA primarily results from graft dysfunction; however, iron deficiency, drug toxicity, and posttransplant inflammation also play a role. PTA is more severe compared with the anemia in glomerular-filtration-rate matched patients with native chronic kidney disease. Treatment of PTA is directed toward the underlying cause. Erythropoiesis stimulating agents (ESA) are effective; however, their use is limited in the transplant setting. Timely diagnosis and treatment of PTA are vital to prevent long-term adverse outcomes in pediatric transplant recipients.
Original language | English (US) |
---|---|
Article number | 929504 |
Journal | Frontiers in Pediatrics |
Volume | 10 |
DOIs | |
State | Published - Jun 20 2022 |
Bibliographical note
Publisher Copyright:Copyright © 2022 Kouri, Balani and Kizilbash.
Keywords
- anemia
- erythropoietin
- hepcidin
- iron deficiency
- pediatric kidney transplant
PubMed: MeSH publication types
- Journal Article
- Review